Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder
Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...
Finance
Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion...
GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...
Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) announced plans for a private placement of up to...
Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...
Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...
Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...
Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...
Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement for Boston Scientific...
Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) announced its intention to acquire 100% equity of...
Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...
Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
OTR Therapeutics Series-A Raises $100M for Neurology Pipeline
OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...
New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...
Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...